Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $139 | $0 | $0 |
| G&A Expenses | $669 | $490 | $531 | $569 |
| SG&A Expenses | $669 | $490 | $531 | $569 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$139 | $0 | $0 |
| Operating Expenses | $669 | $490 | $531 | $569 |
| Operating Income | -$669 | -$490 | -$531 | -$569 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $233 | $262 | $252 | $178 |
| Pre-Tax Income | -$436 | -$228 | -$279 | -$391 |
| Tax Expense | $23,194 | $12 | $0 | $0 |
| Net Income | -$23,630 | -$240 | -$279 | -$391 |
| % Margin | – | – | – | – |
| EPS | -1.64 | -0.017 | -0.02 | -0.027 |
| % Growth | -9,720.4% | 14.4% | 28.8% | – |
| EPS Diluted | -1.64 | -0.017 | -0.02 | -0.027 |
| Weighted Avg Shares Out | 14,452 | 14,338 | 14,321 | 14,294 |
| Weighted Avg Shares Out Dil | 14,452 | 14,338 | 14,321 | 14,294 |
| Supplemental Information | – | – | – | – |
| Interest Income | $233 | $262 | $252 | $178 |
| Interest Expense | $0 | $176 | $0 | $0 |
| Depreciation & Amortization | $43 | $363 | -$40 | $122 |
| EBITDA | -$669 | $262 | -$531 | -$569 |
| % Margin | – | – | – | – |